Asao Tetsuhiko

アサオテツヒコ | Asao Tetsuhiko

Affiliation and department：
Other affiliations (2)：

Weill Cornell Medicine Cell and Developmental Biology, Drukier Institute for Children's health and Meyer Cancer Center Visiting Fellow
Memorial Sloan Kettering Cancer Center Thoracic Surgery Survice Visiting Investigator

Research field (4)： Cell biology , Tumor biology , Respiratory medicine , Tumor diagnostics and therapeutics

Research keywords (6)： Extracellular Vesicles , Malignant mesothelioma , Thymic malignancy , Cancer immunotherapy , Thoracic oncology , Lung cancer

Research theme for competitive and other funds (2)：

2019 - 2022 がん精巣抗原POTEの腫瘍免疫における役割の解明と免疫療法への応用
2014 - 2017 The genomic and epigenomic landscape in thymic carcinoma

Papers (58)：

Masahiro Torasawa, Takehito Shukuya, Kohei Uemura, Takuo Hayashi, Toshihide Ueno, Shinji Kohsaka, Yoshihiro Masui, Yukina Shirai, Makiko Okura, Tetsuhiko Asao, et al. Lymphangioleiomyomatosis as a potent lung cancer risk factor: Insights from a Japanese large cohort study. Respirology (Carlton, Vic.). 2024
Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, Tetsuro Kondo, Shuji Murakami, Yoshimasa Shiraishi, Hisao Imai, Daijiro Harada, Kazutoshi Isobe, Hidetoshi Itani, et al. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study). Clinical cancer research : an official journal of the American Association for Cancer Research. 2024
Tsukita, Y., Tozuka, T., Kushiro, K., Hosokawa, S., Sumi, T., Uematsu, M., Honjo, O., Yamaguchi, O., Asao, T., Sugisaka, J., et al. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer. JAMA Oncology. 2024
Nishioka, N., Imai, H., Endo, M., Notsu, A., Doshita, K., Igawa, S., Yokouchi, H., Ninomiya, T., Tokito, T., Soda, S., et al. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101). Targeted Oncology. 2024
Noritake, O., Nakamura, S., Kinoshita, F., Aokage, K., Asao, T., Matsuura, Y., Chen-Yoshikawa, T.F. Prognostic impact of adjuvant therapy for cisplatin-unfit patients with non-small-cell lung cancer: A multicenter analysis. Lung Cancer. 2024. 188

ｍore...

MISC (25)：

白石祥理, 久保田馨, 中道真仁, 三角俊裕, 近藤哲郎, 岡本勇, 湊浩一, 原田大二郎, 磯部和順, 井谷英敏, et al. III期非小細胞肺癌に対する化学放射線療法完遂直後のデュルバルマブ療法の第II相試験(TORG1937). 肺癌. 2022. 62. 6. 582-582
大熊智子, 三森友靖, 宿谷威仁, 増田孝一, 三浦啓太, 黒川加奈, 早川乃介, 徐仁美, 宮脇太一, 朝尾哲彦, et al. Retrospective study of steroid therapy to lung cancer patients with pneumonitis caused by immune checkpoint inhibitors (ICI). 日本呼吸器学会誌(Web). 2022. 11
舛井嘉大, 宿谷威仁, 片岡峻一, 阿部瞳, 黒川加奈, 中村育子, 宮脇太一, 濃沼淑芳, 朝尾哲彦, 金丸良太, et al. 進行非小細胞肺癌の治療成績向上に伴い異次性二次癌がどのような影響を与えているか?. 日本肺癌学会学術集会号. 2022. 63rd (CD-ROM)
嶋村尚子, 宿谷威仁, 朝尾哲彦, 早川乃介, 高遼, 光石陽一郎, 田島健, 嶋田奈緒子, 高橋史行, 高橋和久. Examination of long-term survival factors in advanced EGFR mutation/ALK fusion gene-positive NSCLC. 日本呼吸器学会誌(Web). 2021. 10
三浦啓太, 宿谷威仁, 朝尾哲彦, 虎澤匡洋, 早川乃介, 松本直久, 嶋村尚子, 高遼, 光石陽一郎, 田島健, et al. Efficacy of first line Pembrolizumab in recurrent non-small cell lung cancer after radical treatment. 日本呼吸器学会誌(Web). 2021. 10

ｍore...

Lectures and oral presentations (108)：

Pembrolizumabによる免疫関連有害事象の腸炎に対し、ベドリズマブを投与した肺扁平上皮癌の1例
(肺癌 2021)
ペムブロリズマブによる免疫関連腸炎に対しベドリズマブを投与した肺扁平上皮癌の1例
(肺癌 2021)
神経内分泌マーカーは小細胞肺癌において,化学療法の効果予測や予後予測に有用か?
(肺癌 2021)
当院でペムブロリズマブ投与後に発症した副腎皮質機能低下症の後方視的検討
(肺癌 2021)
オンコマインDx Target TestマルチCDxシステムでEGFR変異とMET Exon 14 skipping(METex14)が同時に検出されたが、ArcherMETではMETex14が検出されなかった肺腺がんの1例
(肺癌 2021)

ｍore...

Association Membership(s) (5)：

THE JAPANESE CANCER ASSOCIATION , THE JAPANESE RESPIRATORY SOCIETY , The Japanese Society of Medical Oncology , THE JAPAN LUNG CANCER SOCIETY , 日本内科学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page